REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.

REGENXBIO Inc.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam Pharmaceuticals, Inc.

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.

Instil Bio, Inc.

Kebotix provides R&D solutions through enterprise AI customized for materials discovery, leveraging cloud technologies, machine learning, and automation.

Kebotix

REGENXBIO is seeking to improve lives through the curative potential of gene therapy. The company develops gene therapy product candidates in the retinal, metabolic and neurodegenerative therapeutic areas.

Metric
Company Name	REGENXBIO Inc.	Alnylam Pharmaceuticals, Inc.	Instil Bio, Inc.	Kebotix
Symbol	RGNX	ALNY	TIL
MSH ID	COM:REGENXBIO	COM:ALNYLAM	COM:INSTILBIO	COM:KEBOTIX
Market	STOCKS	STOCKS	STOCKS	PRIVATE
Sector	Healthcare	Healthcare	Healthcare	Technology
Industry	Biotechnology	Biotechnology	Biotechnology	Materials Science
Country	US	US	US	US
Stage				Venture Round
Employee Count	344	2.10K	49
Website	regenxbio.com	alnylam.com	instilbio.com	kebotix.com
LinkedIn
Founders

Metric
Market Cap	529.01M	32.60B	65.10M
Enterprise Value
Monthly Web Traffic		55.97K	12.72K	187
Web Traffic Growth		0.89	-0.76	-0.83
Valuation
Raised Capital		900M		5.00M

Metric
Revenue	90.24M	1.83B
Revenue (LTM)
Revenue (NTM)
Gross Profit	35.71M	1.52B
EBITDA	-250.81M	-228.12M
Operating Income	-268.13M	-282.18M
Net Income	-263.49M	-440.24M
EPS	-6.02	-3.52
Diluted EPS	-6.02	-3.52
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.54	0.87
Operating Profit Margin	-2.77	0.04
EBITDA Margin	-2.78	-0.12
Net Profit Margin	-2.71	-0.03
Return on Equity	-0.68	1.67
Return on Assets	-0.41	-0.02
Return on Capital Employed	-0.51	0.03

COM:REGENXBIO

REGENXBIO

Last Close

9.18

22/11 21:00

Market Cap

529.01M

Beta: -

Volume Today

684.38K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-2.05	-42.10
P/B Ratio	1.49	-129.43
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	12.04	16.84
EV Multiple	-1.51	326.32

Metric
Days Sales Outstanding	103.00	68.92
Days Payables Outstanding	205.86	97.72
Days Inventory Outstanding	0.00	128.53
Operating Cycle	106.54	187.09
Cash Conversion Cycle	-17.79	104.98
Asset Turnover	0.16	0.58

Metric
Operating Cash Flow	-218.41M	104.16M
Free Cash Flow	-228.37M	41.95M
Cash Flow to Debt	-2.13	0.15
Operating Cash Flow/Sales	-2.15	0.16
Free Cash Flow Yield	-0.43	-0.00

Metric
Cash & Equivalents	34.52M	812.69M
Accounts Receivable	3.94M	-87.94M
Inventory		89.15M
Goodwill
Debt to Capitalization	0.22	1.20
Debt to Assets	0.14	0.34
Current Ratio	2.87	3.14
Quick Ratio	3.59	3.07

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.42	0.13
R&D to Revenue	2.41	0.58
SG&A to Revenue	0.91	0.35